Since no one has objected to more generalized investment considerations, I'll tell Sector Investor what I have chosen to do. This is not advice, do your own homework, etc.
Although biotech will soon be the industry with the most technological advancements, I think it's imprudent (for me) to be more than 25% weighted in it.
Within that 25%, I like to hold at least ten investments. The company in which I have the most confidence is Sepracor, due to a diverse and late-stage pipeline supported by a wide patent portfolio, major partnerships, diversified business model, and strong balance sheet. In fact, analysis of Sepracor's low risk business plan (improving existing drugs) lead me to DEPO and ADRX as well.
ArQule, the great chemistry company, also merits consideration for the long term. And finally, Ariad has fascinating techology, top-notch scientists, and a new genomics institute, but is selling for a pittance. I own all of these, and more within the biotech sector. |
